Log In
Print this Print this

Roclatan, netarsudil/latanoprost (PG324)

  Manage Alerts
Collapse Summary General Information
Company Aerie Pharmaceuticals Inc.
DescriptionFixed-dose combination of Rhopressa netarsudil 0.02%, a dual inhibitor of Rho kinase and the norepinephrine transporter, and latanoprost 0.005%, a prostaglandin analog
Molecular Target Rho kinase ; Norepinephrine transporter
Mechanism of ActionRho kinase inhibitor; Norepinephrine transporter (NET) inhibitor
Therapeutic ModalitySmall molecule: Combination
Latest Stage of DevelopmentPhase III
Standard IndicationGlaucoma
Indication DetailsTreat glaucoma and ocular hypertension; Treat intraocular pressure (IOP) in glaucoma and ocular hypertension patients
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today